TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03878134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHOTON COUNTING CT Scanner
Description: Enrolled patients will undergo the requested clinical diagnostic CT study on the investigational system using the standard detector, with or without IV and/or oral contrast as indicated and an limited scan of one body region using the PCCT detector. Both scans are able to be performed on the same scanner during the same examination.
Study: NCT02839499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RU sleeping®
Description: Each patient included in the study has a test by RU-sleeping. The diagnosis of obstructive sleep apnea syndrome will be asked for an index of respiratory events estimated as greater than or equal to 10.

Intervention type: DEVICE
Group type: OTHER
Intervention: RU sleeping®
Description: Each patient included in the study has a test by RU-sleeping. The diagnosis of obstructive sleep apnea syndrome will be asked for an index of respiratory events estimated as greater than or equal to 10.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autonomy scale (ADL and AGGIR)
Description: autonomy data

Intervention type: OTHER
Group type: OTHER
Intervention: autonomy scale (ADL and AGGIR)
Description: autonomy data

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: various activity scale (IADL)
Description: activity of life data

Intervention type: OTHER
Group type: OTHER
Intervention: various activity scale (IADL)
Description: activity of life data
Study: NCT03797638

Intervention type: DEVICE
Group type: OTHER
Intervention: Finger Force Manipuladum (FFM)
Description: Tasks performed with the device Finger Force Manipuladum (FFM), to assess abilities such as finger individuation but also fine finger force control, finger movement regularity and speed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Finger Force Manipuladum (FFM)
Description: Tasks performed with the device Finger Force Manipuladum (FFM), to assess abilities such as finger individuation but also fine finger force control, finger movement regularity and speed.
Study: NCT03660410

Intervention type: OTHER
Intervention: Anamnesis
Description: A detailed anamnesis should be carried out in order to know the habits, the presence of systemic pathologies, the use of medication

Intervention type: OTHER
Intervention: Anamnesis
Description: A detailed anamnesis should be carried out in order to know the habits, the presence of systemic pathologies, the use of medication

Intervention type: OTHER
Intervention: Anamnesis
Description: A detailed anamnesis should be carried out in order to know the habits, the presence of systemic pathologies, the use of medication

Intervention type: OTHER
Intervention: Oral clinical examination
Description: Clinical examination should be carried out evaluating the presence of caries, tooth loss, periodontal condition, occlusal factors

Intervention type: OTHER
Intervention: Oral clinical examination
Description: Clinical examination should be carried out evaluating the presence of caries, tooth loss, periodontal condition, occlusal factors

Intervention type: OTHER
Intervention: Oral clinical examination
Description: Clinical examination should be carried out evaluating the presence of caries, tooth loss, periodontal condition, occlusal factors
Study: NCT05411796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tampax menstrual cup
Description: regular flow size

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tampax menstrual cup
Description: regular flow size

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Other menstrual cup
Description: size 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Other menstrual cup
Description: size 1
Study: NCT04625738

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells
Description: Ex vivo expanded Wharton's Jelly derived mesenchymal stem cells will be infused at day 0, day 3 and day 5 (+/- 1 day), in patients with moderate to severe ARDS with a mechanical ventilation.~day 0: 1.10\^6 MSC/kg day 3: 0.5. 10\^6 MSC/kg day 5: 0.5 . 10\^6 MSC/kg

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Only the vehicle solution, without MSCs, containing albumin 4% , NaCl 0,9% and ACD will be injected to patients at day 0, 3 and 5 (+/-1 day).
Study: NCT01971138

Intervention type: OTHER
Intervention: this is a survey
Study: NCT00219375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sivelestat sodium hydrate
Description: 0.2 mg/kg/hr continuous i.v. infusion - up to 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sivelestat sodium hydrate
Description: 0.2 mg/kg/hr continuous i.v. infusion - up to 14 days
Study: NCT04055116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buffered Lidocaine
Description: Investigator will prepare 1:10 dilution of sodium bicarbonate to 2% lidocaine with 1:100,000 epinephrine on one occasion. 8.4% Sodium Bicarbonate will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buffered Lidocaine
Description: Investigator will prepare 1:10 dilution of sodium bicarbonate to 2% lidocaine with 1:100,000 epinephrine on one occasion. 8.4% Sodium Bicarbonate will be used.
Study: NCT04409041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-Dose Naltrexone
Description: Based on the promising evidence, we propose using low-dose naltrexone at a daily dose of 3mg to treat lichen planopilaris and frontal fibrosing alopecia. The patients would be continued on their other medications for these conditions. The study would be open-label, so all participants would receive the low-dose naltrexone. Patients would be seen at 0,3,6 and 12 months to monitor their progress.
Study: NCT00200954

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic bacteria
Description: 3 x 10e9 CFU of a mixture of probiotic bacteria, once daily to the pregnant mothers last 6 weeks of pregnancy.To their offspring during the first year of life.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consists of the carrier of the probiotic bacteria mixture, i.e. rice starch and maltodextran
Study: NCT04913428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interdigital exercise
Description: Patient asked to sit in upright position interlocking their fingers with inhaling deeply bringing the arms up and exhaling through mouth while bring the arm down.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blow-Bottle technique
Description: For blow bottle 20cm of bottle filled with 10cm of water in which a tube of length 35- 40cm inserted with the inner diameter of ≥8mm(21).Patient is asked to form bubbles in bottle by exhaling in bottle performing Forced Expiratory Techniques.
Study: NCT02098161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smac Mimetic LCL161
Description: Given PO
Study: NCT02489227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHS-1420

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHS-1420

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Study: NCT03211195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT03151356

Intervention type: DEVICE
Intervention: Measurement of Prostate Health Index (PHI)
Description: Use of a diagnostic tool to predict prostate biopsy outcome: measurement of total and free PSA as well as the \[-2\]proPSA and calculation of The Prostate Health Index according to the following formula: Prostate Health Index (PHI) = \[p2PSA /fPSA\] x √tPSA
Study: NCT02729649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ArmAssist robotic training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extended conventional therapy
Study: NCT03672903

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Weight Vest
Description: A vest with added weights up to a maximum of 15 kg.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Weight Vest
Description: A vest with added weights up to a maximum of 15 kg.
Study: NCT04441294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACE-Plus
Study: NCT02326142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBE001
Description: OBE001 dispersible tablets for a single oral dose a day for up to 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dispersible tablets for a single oral dose a day for up to 7 days.
Study: NCT02720575

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Consumption of capsule/bread with vitamin D

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Consumption of capsule/bread with vitamin D

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Consumption of capsule/bread with vitamin D

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Consumption of capsule/bread with vitamin D

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consumption of capsule/bread with vitamin D

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consumption of capsule/bread with vitamin D
Study: NCT01778166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immuno-enhanced
Description: Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C enteral nutrition fluid concerning omega-3-unsaturated fatty acids 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard early enteral nutrition
Description: Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C standard enteral nutrition fluid 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube
Study: NCT01879696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECSPRESS catheter with active vacuum
Study: NCT05023694

Intervention type: OTHER
Intervention: Video recordings
Description: In the first phase it will proceed to completion of the registration system by collecting data revivals and video recordings.~In a second phase, the video is displayed and analysis of the resuscitation performance will take place. We will identify and make a registration of incidents. At this point the observational descriptive analysis will take place.~Third phase: to develop preventive measures necessary to limit the number of incidents or to contain or minimize adverse effects resulting thereof: restructure and adapt the protocol.

Intervention type: OTHER
Intervention: Video recordings after corrective measures in adverse events
Description: Fourth phase: Training department staff on improvements to optimize performance times protocol using simulation.~Fifth stage: final implementation of corrective measures of adverse events during the performance resuscitation.~Sixth stage: successive evaluations of impact of corrective measures. With this evaluation, it will be held another descriptive case series. With the secondary formulate hypothesis after analysis of the errors, the protocol is optimized and measured if errors are minimized: analytical observational prospective cohort study.
Study: NCT01000246

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: influenza virus vaccine (influvac or vaxigrip)
Description: one i.m. dose of 0.5 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: influenza virus vaccine (influvac or vaxigrip)
Description: one i.m. dose of 0.5 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: influenza virus vaccine (influvac or vaxigrip)
Description: one i.m. dose of 0.5 mL
Study: NCT04577690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with epinephrine 1:200000 by PECS block and wound infiltration
Description: The anesthesiologist will administer bupivacaine 0.25% with epinephrine 1:200000 by PECS block after induction of anesthesia before surgical incision. The EP cardiologist will also administer bupivacaine 0.25% with epinephrine 1:200000 by infiltrating the wound after surgery is complete.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% with epinephrine 1:200000 by wound infiltration only
Description: The EP cardiologist will administer Bupivacaine 0.25% with epinephrine 1:200000 by infiltrating the wound after surgery is complete.
Study: NCT01622205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very early supported discharge (VESD)
Description: A rehabilitation team made up of physiotherapists, occupational therapists and a stroke nurse from the stroke care unit continues the rehabilitation in the patient's home. The intervention has a person-centered approach which is based on who the person is: their context, their history, their next of kin, their individual strengths and weaknesses (28). Goal setting using questions as in the Canadian Occupational Performance Measure (29) takes part before the discharge. Examples of goals can be: to be able to go to the local store to buy milk, to be able to hang the laundry or to be able to travel on the tram to the daughter or how to manage the bills.

Intervention type: OTHER
Group type: OTHER
Intervention: Ordinary rehabilitation
Description: Ordinary rehabilitation
Study: NCT00907920

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00080223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: up to 3600 mg/day of pirfenidone given orally administered in divided doses three times daily with food, for the duration of the study
Study: NCT03362515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: furosemide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT06472804

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT02584309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexrazoxane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Study: NCT01221259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2212
Description: single ascending doses ranging from 10mg to 250mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: a single dose of matching placebo
Study: NCT04390152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wharton's jelly derived Mesenchymal stem cells.
Description: IV Wharton's jelly derived Mesenchymal stem cells, two doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)
Description: Standard therapy as per hospital protocol, hydroxychloroquine 400mg + Lopinavir/Ritonavir 400/100 or azithromycin 500mg and Placebo
Study: NCT03860896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB004
Description: GB0004 high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01721941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I Dose level 3
Description: The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
Study: NCT03860896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB004
Description: GB004 low dose
Study: NCT01550874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity behavior-change counselling
Description: Participants in the experimental group will be motivated by augmented behavior modification strategies aiming to increase performance by: (i) having access to the pedometer web page that allows them to view their automatically calculated goals, and (ii) get feedback about performance toward goals.
Study: NCT02292628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusion of mesenchymal stem cells from adipose tissue

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Infusion of placebo
Study: NCT02404363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel tablets 75 mg for six months:~In case of treatment with aspirin \< or = 75 mg/d or prophylactic LMWH --\> clopidogrel 75 mg/d If aspirin = 0 + LMWH = 0 --\> clopidogrel 150 mg/d x 7days then 75mg/d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets 75 mg for six months:~In case of treatment with aspirin \< or = 75 mg/d or prophylactic LMWH --\> placebo 75 mg/d If aspirin = 0 + LMWH = 0 --\> placebo 150 mg/d x 7days then 75mg/d
Study: NCT02411331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol 40% + Enoxaparine 400UI/ml

Intervention type: DRUG
Group type: OTHER
Intervention: Vancomycine 5 mg/ml + Héparine 2500UI/ml
Study: NCT00224211

Intervention type: BEHAVIORAL
Intervention: Music
Study: NCT01870622

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flow waves
Description: Flow waves will be used to confirm correct tube placement in newborn infants.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ECO2
Description: ECO2 will be used to confirm correct tube placement in newborn infants.
Study: NCT00699972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007 (perampanel)
Description: 8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007 (perampanel)
Description: 12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
Study: NCT00160316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 Mg Estradiol and 2.5 Mg Dydrogesterone
Description: p.o. daily
Study: NCT01305031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resuscitation
Description: Use of inspiratory fraction of oxygen needed to achieve oxygen saturation in the preset limits 85-92%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 100% oxygen
Description: Use of 100% oxygen needed to achieve oxygen saturation in the preset limits 85-92%
Study: NCT00014235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given IV or PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03236818

Intervention type: DRUG
Group type: OTHER
Intervention: ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
Description: Combination of an ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
Study: NCT03937076

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PECS II block
Description: Pectoral muscles Nerve block for postsurgical pain, PECS II, based on BUPIVACAINE:~Pectoral muscles nerve block is a procedure in which local anesthetic is injected into two sites.~1. between the major and minor pectoral muscles, in order to anesthetize the lateral and medial nerve. This injection is referred to as PECS I block.~2. between the minor pectoral muscle and the anterior serratus muscle, in order to anesthetize the intercostal nerves.
Study: NCT03586739

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endovascular angioplasty using covered stents
Description: Primary endovascular angioplasty using one or several covered stents

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endovascular angioplasty using bare metal stents
Description: Primary endovascular angioplasty using one or several bare metal stents

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duplex-scan
Description: a Duplex-scan will be performed during patient follow up.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duplex-scan
Description: a Duplex-scan will be performed during patient follow up.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: computerized tomography scan (CT-scan)
Description: a CT-scan will be performed in the event of symptoms of recurrence or restenosis as confirmatory exam according to clinical practice during patient follow up.~The CT-scan will be mandatory at 12 and 24 months if it has not been planned in the current practice follow-up.